Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biopharmaceutical company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The DYN news feed highlights company announcements related to its neuromuscular pipeline, corporate strategy and financial position.
News coverage for Dyne commonly includes updates on its lead clinical programs, zeleciment rostudirsen (z-rostudirsen, DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping and zeleciment basivarsen (z-basivarsen, DYNE-101) for myotonic dystrophy type 1 (DM1). Investors can follow topline and long-term data readouts from the Phase 1/2 DELIVER and ACHIEVE trials, including biomarker results, functional endpoints, safety and tolerability findings, and regulatory milestones such as Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug designations.
The DYN news stream also features information on Dyne’s preclinical programs in facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease, presentations at scientific and investor conferences, and corporate developments such as public offerings of common stock, loan agreements and board appointments. Periodic financial results and business updates provide additional context on cash runway, planned regulatory submissions and the company’s preparation for potential commercialization of its neuromuscular therapies.
By monitoring this page, readers can review Dyne’s press releases on clinical progress, regulatory interactions, financing transactions and conference presentations in one place. This historical record of company communications helps investors, analysts and other stakeholders understand how Dyne’s FORCE platform, pipeline and corporate activities are evolving over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Dyne Therapeutics, Inc. (DYN) announced that DYNE-251, its investigational therapy for Duchenne muscular dystrophy (DMD), received FDA orphan drug and rare pediatric disease designations. This marks a significant step as DYNE-251 undergoes evaluation in the Phase 1/2 DELIVER clinical trial. The trial aims to enroll 46 males aged 4 to 16 with DMD mutations suitable for exon 51 skipping. Initial data is expected in the second half of 2023, focusing on safety and dystrophin levels. DYNE-251 uses a novel delivery method targeting muscle cells, showing promising results in preclinical studies, including a favorable safety profile and effective exon skipping.
Dyne Therapeutics (Nasdaq: DYN) announced key developments during the MDA Clinical & Scientific Conference held March 19-22, 2023. The company showcased its global Phase 1/2 clinical trials, ACHIEVE and DELIVER, evaluating DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy (DMD), respectively. Initial data from both trials is expected in the second half of 2023. Additionally, the FORCE™ platform demonstrated successful exon skipping and dystrophin restoration in preclinical models, indicating potential for treating DMD. The company aims to address the urgent need for better therapies in muscle diseases.